Table 1.

List of FDA-approved single biomarkers for detection of EOC.

Criteria	Value/ Target Cohort	Biomarkers
		CA125 U/mL	HE4 pM/L	CA19-9 U/mL	CEA ng/mL
Type		Mucinous Glycoprotein	Glycoprotein	Mucinous Glycoprotein	Glycoprotein
Diagnostic		✓	✓	✓	✓
Prognosis		✓	✓	✓
Monitoring				✓	✓
FDA Approval (Year)		1981	2008	2002	1985
Cut-off		35	>70 or 140	<37 or 27	2.5–5
MW (kDa)		>200	25	1000	180
Immunoassay Technique: ECLIA/Magnetic bead assay	SP%	>60–80	>96–100	79.01	>88–100
	SN%	>60–96	>63–83	35.71	>38–66.3
	Benign	9.02–54.92	49.01–54.49	19.15	2.71
	Malignant	368	245.9
	Late-stage	184.62	234.77	45.61	9.27
Ref.		[60,61]	[60,61,62,63]	[36,54,64]	[52,64,65,66]

Abbreviations: CA 125: cancer antigen 125; HE4: human epididymis secretory protein 4; CA19-9: carbohydrate antigen 19-9; CEA: carcinoembryonic antigen; FDA: Food and Drug Administration; M_W: Molecular weight; ECLIA: Electrochemiluminescence Immunoassay; S_P%: Specificity; S_N%: Sensitivity. ✓-Used as biomarker.